PAK6: a potential anti-cancer target

Authors

  • Chan-Chan Gong Xuzhou Medical University, Department of Pathology
  • Tong-Tong Li Xuzhou Medical University, Department of Pathology
  • Dong-Sheng Pei Xuzhou Medical University, Department of Pathology https://orcid.org/0000-0002-8053-3741

DOI:

https://doi.org/10.1590/s2175-97902019000318315

Keywords:

PAK6, androgen Receptor (AR), cancer therapy, miRNAs

Abstract

p21-activated kinase 6 (PAK6) is a member of the PAK family of serine/threonine kinases that are known effectors of Rho GTPases Cdc42 and Rac. PAKs regulate a large number of complex cellular mechanisms, including cell motility, morphology, and tumor development. PAK6, initially cloned as an interacting partner of the androgen receptor (AR), is associated with an array of cellular processes implicated in tumor progression. However, the full biological implications of PAK6 activity during cancer remain poorly understood. In this review, we assess our current understanding of the physiological roles of classical PAK6 functionality in mammals, in addition to its emerging role in tumorigenesis.

Downloads

Download data is not yet available.

Downloads

Published

2020-12-09

Issue

Section

Review

How to Cite

PAK6: a potential anti-cancer target. (2020). Brazilian Journal of Pharmaceutical Sciences, 56, e18315. https://doi.org/10.1590/s2175-97902019000318315